Armistice Capital, a hedge fund managing more than $7 billion in assets, has built a portfolio with substantial concentration in healthcare, particularly biopharmaceutical companies developing treatments for rare diseases, neurological conditions, and cardiovascular medicine. Quarterly 13F filings submitted to the Securities and Exchange Commission show Armistice consistently among the more active institutional investors in the healthcare sector, alongside other specialist managers such as Baker Bros. Advisors, RTW Investments, and Rock Springs Capital.
Hedge funds with healthcare mandates have drawn attention from market observers who track institutional positioning because their moves often signal conviction around regulatory or clinical catalysts. Armistice Capital, like its peers, maintains positions in biopharmaceutical companies where FDA approval timelines, clinical trial readouts, and pipeline updates can drive meaningful price movements. The fund’s filings reflect both long-term holding patterns in some positions and more dynamic activity in others, including the use of options contracts in select holdings.
Among Armistice’s disclosed positions, the fund holds approximately 5.43 million shares of PTC Therapeutics, representing roughly 6.86% of shares outstanding and placing it among the top five institutional holders of that stock. Larger passive holders, including Vanguard Group with approximately 10.9% and BlackRock with approximately 9.8%, account for a greater share of total institutional ownership, though their mandates differ from those of active managers. Armistice also maintains positions in Supernus Pharmaceuticals, Travere Therapeutics, and Cytokinetics, each a company focused on disease areas with limited treatment options and active regulatory pipelines. Institutional inflows into PTC Therapeutics alone totaled approximately $859 million against $456 million in outflows over a recent trailing period, reflecting sustained net buying across a broad range of holders.
Other institutional managers have taken similar approaches. Millennium Management, Wellington Management, and Driehaus Capital Management have each added or maintained positions in overlapping healthcare sub-sectors. For many of these funds, the combination of binary catalysts and identifiable valuation events makes biopharma stocks attractive within a broader active management context. Armistice Capital’s concentration in healthcare, alongside additional exposure in retail and consumer companies, places it among a group of active managers whose portfolio construction tracks the ongoing development of specialty drug pipelines.